Motetis (Tetrabenazine)

Tetrabenazine, the active ingredient in Motetis, is a VMAT2 inhibitor presented as an oral formulation for oral use. It is indicated for adult patients with hyperkinetic movement disorders such as Huntington's disease and tardive dyskinesia, helping to reduce involuntary movements that interfere with daily activities.

GNH USA supplies Motetis as a licensed, GDP‑compliant international pharmaceutical supplier, delivering quality‑assured medication to hospitals, pharmacies and clinics worldwide in accordance with EU regulatory standards and supports reliable supply chains for global healthcare providers.

Motetis (tetrabenazine) acts on the vesicular monoamine transporter 2 pathway to control abnormal involuntary movements.

Huntington's disease (chorea): reduces the severity and frequency of choreiform movements, improving motor function. Tardive dyskinesia (drug‑induced involuntary movements): decreases the intensity of facial and limb dyskinesias. Other hyperkinetic movement disorders (off‑label): may provide symptomatic relief of involuntary movements.

Tetrabenazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Fatigue - Somnolence - Dizziness - Depression - Weight loss

Serious or Rare Side Effects: - Severe depression or suicidal ideation - QT interval prolongation leading to arrhythmia - Neuroleptic malignant‑like syndrome - Parkinsonism - Hepatic toxicity - Agranulocytosis

When prescribing tetrabenazine, clinicians should observe several safety considerations.

Monitor for depression: assess mood regularly and intervene promptly if worsening occurs. Assess cardiac function: obtain baseline ECG and monitor QT interval during therapy. Avoid abrupt discontinuation: taper dose under medical supervision to prevent withdrawal phenomena. Use caution in hepatic impairment: dose adjustment may be required based on liver function. Avoid concomitant MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. Store at ambient temperature: keep in original container, protect from moisture and light.

Tetrabenazine interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Concomitant MAO inhibitors: may cause hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase tetrabenazine plasma levels, raising toxicity risk. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may enhance serotonergic effects. - Antipsychotics (especially dopamine antagonists): may potentiate motor side effects. - Other dopaminergic agents (e.g., levodopa): may reduce therapeutic efficacy.